RIAs for hemostatic system activation were employed to study patients who were anticoagulated with warfarin. The mean prothrombin fragment F1+2 concentration in stably anticoagulated individuals without an inherited thrombotic diathesis (mean prothrombin time [PI] ratio WPT of patient/PT of normal plasma pool] = 1.74) was 0.231 nM as compared with a mean plasma F1+2 level of 1.68 nM for a nonanticoagulated control group (P < 0.0001). The initiation of oral anticoagulants in two subjects who did not exhibit protein C deficiency led to a paradoxical increase in Fl+2 levels during the first day of therapy. We have also shown that a relatively low intensity regimen of warfarin (PT ratio < 1.2) may reduce elevated concentrations of F1+2 into the normal range in patients with a history of recurrent thromboembolism. The mean F1+2 level in antithrombin-deficient individuals on warfarin was significantly elevated (mean = 0.714 nM) as compared with that in anticoagulated subjects with protein C deficiency (mean = 0.205 nM) or in those without an inherited thrombotic disorder (P < 0.01) at equivalent levels of intensity of oral anticoagulation. We therefore conclude that the effect of warfarin on hemostatic system activation is modulated by the endogenous heparan sulfate-antithrombin mechanism.
Introduction
The conversion of prothrombin to thrombin is the central event in the coagulation of blood. This reaction takes place at an appreciable rate under physiologic conditions only in the presence of Factor Xa, Factor Va, calcium ions, and platelets. During this process, the amino terminus of the prothrombin molecule is released as the inactive F,+2 fragment in conjunction with the generation of thrombin. Once produced, this serine protease is able to cleave two pairs of peptides, fibrinopeptides A (FPA)' and B, from fibrinogen that permits the resulting fibrin to polymerize into an insoluble clot. Thrombin can also rapidly activate protein C by binding to thrombo- 1. Abbreviations used in this paper: asp, aspartic acid; FPA, fibrinopeptide A; gla, carboxyglutamic acid; PCP, protein C activation peptide; PT, prothrombin time. modulin on vascular endothelial cells at a 1:1 stoichiometric ratio of enzyme to receptor (1) (2) (3) . The thrombin-thrombomodulin complex is then able to scission an Arg,2-Leu,3 bond at the amino-terminal end of the heavy chain of protein C that releases a small dodecapeptide of Mr of -1,400 (4) . Once generated, activated protein C can inhibit the platelet-dependent conversion of prothrombin to thrombin via Factor Xa by inactivating Factor VIIIa (5) and platelet-bound Factor Va (6) . Protein S is able to enhance the binding of activated protein C to phospholipid-containing membranes and to accelerate the proteolytic inactivation of the two activated cofactors (7, 8) . The enzymatic activity of thrombin can also be directly inhibited by the plasma protein antithrombin resulting in the formation ofa stable enzyme-inhibitor complex. This interaction is accelerated by heparan sulfate proteoglycans associated with the vascular endothelium (9-1 1).
Based upon recent advances in our knowledge of the biochemistry ofthe coagulation system, a series of highly sensitive and specific immunoassays have been developed that can quantitate the activities of various steps of the hemostatic mechanism in vivo at the subnanomolar level. We have developed RIAs for the F,+2 fragment and the protein C activation peptide (PCP) that measure the cleavage of the prothrombin molecule by Factor Xa (12, 13) and the scission ofprotein C by the thrombin-thrombomodulin complex (14) , respectively. Nossel and co-workers (15, 16) had previously developed an immunoassay for FPA that monitors the proteolysis of fibrinogen by thrombin. All individuals exhibit measurable amounts of these markers. We have previously observed that substantial elevations in Factor Xa activity but not thrombin activity regularly occur in the blood of many individuals with hereditary deficiencies of antithrombin (17) and protein C. 2 In this communication, we have demonstrated that F,+2 levels are markedly suppressed in stably anticoagulated patients receiving sodium warfarin, and that a relatively low intensity regimen of this medication may reduce elevated plasma levels of this fragment into the normal range in patients with a history of recurrent thromboembolism. We have also examined the effect of warfarin on this marker of hemostatic system activation in patients with deficiencies of antithrombin or protein C.
Methods
Collection and processing ofblood samples. Venipunctures were performed atraumatically with 19-or 2 1-gauge butterfly infusion sets using a two-syringe technique. Blood samples were drawn into plastic syringes preloaded with the appropriate solutions as described below. These included: (a) For immunologic measurements of antithrombin, protein C, protein S, and prothrombin, 3.8% (wt/vol) sodium citrate was employed; the ratio oi anticoagulant to blood used was 0.1:0. 9 (vol/vol). (b) "F1+2 and PCP anticoagulant:" (38 mM citric acid, 75 mM sodium citrate, 136 mM dextrose, 6 mM EDTA, 6 mM adenosine, and 25 U/mil heparin; the ratio of anticoagulant to blood employed was 0.2: 1.0 (vol/vol). (c) "FPA anticoagulant:" this preparation was provided by Mallinckrodt, Inc., St. Louis, MO; the ratio ofanticoagulant to blood used was 0.1:0.9 (vol/vol). After collection of blood samples, plasma fractions were obtained by centrifugation at 40C for 15 min at 1,600 g and stored at -80'C before use.
A normal plasma pool was constructed by pooling equal volumes of plasma from 30 control subjects. This population consisted of healthy laboratory and medical personnel between the ages of 20 and 40 yr, who gave a negative history for bleeding as well as thrombosis, and were not taking ady medications at the time of sample collection.
Coagulation studies. Routihe coagulation studies including prothrombin time (PT) and activated partial thromboplastin time were performed by standard laboratory methods (18 (19) . The anticoagulant activity of protein C was determined with a clotting method (Staclot Protein C; American Bioproducts Co., Patsippany, NJ).
The criteria of Bertina et al. were utilized to establish a laboratory diagnosis of a protein C (20) or protein S deficiency state (21) .
Immunoassays. The plasma concentrations of protein C, prothrombin, antithrombin, F1+2, and PCP were determined by double antibody RIA as described in earlier reports from our laboratory (13, 14, 19) . Ahtigenic levels of total protein S wete measured with an immunoradiometric assay technique (21) . The plasma levels of FPA were established by RIA utilizing a kit provided by Mallinckrodt, Inc.
The interassay variability ofthe F1+2 measurement was determined with replicate determinations of a normal plasma pool from 34 separate runs over a 1-yr period. The coefficient of variation was 8%.
Preparation of normal and partially gamma decarboxylated F,+2
for turnover studies. Human prothrombin fragiient F,+2 was purified from 2 liters of fresh frozen plasma. The procedures employed were outlined in a previous publication from our laboratory (17) . Approximately 50% of the gamma carboxygutamic acid (gla) residues of F1,+2 were decarboxylated to glutamic acid by a modification of the techniques described by Poser and Price (22) (12) .
To measure the amount of gla in the normal and partially gamma carboxylated F1+2 samples, -t00 pmol of each protein preparation were hydrolyzed for 22 h in 2 M KOH in sealed tubes at 1 10C after lyophilization (24) . A kfIown amount of '4C-labeled gla ( (26) . Quantitation of eluted amino acids was performed using a Shimadzu C-R3A plotter-integrator. The amounts of gla and asp in each sample were derived by interpolation on linear standard curves constructed with known amounts of gla and asp (Calbiochem-Behring Corp., La Jolla, CA). The number of moles ofgla per mole of protein was determined assuming that one mole of F1+2 contains 33 moles of asp (27) .
'-"I-F,+2 preparation and turnover studies. Radiolabeling of normal and partially gamma decarboxylated F1+2 was accomplished by the method of Greenwood et al. (28) Analysis ofdata. Estimation of relative immunoreactivity, computation ofthe slopes ofthe dose-response curves, as well as determinations ofthe various associated indices were obtained by a least-squares fit of the RIA results to a "four parameter" model as described by Rodbard (29, 30) . Statistical analyses of data were conducted by standard techniques (31) . In most instances, the means are provided with associated standard deviations.
Results
Suppression ofprothrombin activation in patients on oral anticoagulants Fig. 1 . Warfarin is able to interfere with the normal carboxylation mechanism of the liver resulting in the production of vitamin K-dependent proteins with less than their full complement of gla residues. Gla residues enable these proteins to bind to phospholipid surfaces in the presence of calcium ions. This results in a dramatic acceleration in the rate of conversion of vitamin K-dependent coagulation zymogens to their corresponding serine proteases. Normal prothrombin contains 10 mol of gla per mole of protein that are localized to the NH2-terminal region of the F. domain of the molecule. Friedman et al. (33) have observed that prothrombin isolated from the plasma of patients ingesting oral anticoagulants on a chronic basis consists of a wide spectrum of abnormal molecules that contain varying quantities of gla per mole of zymogen. These investigators determined that only 50% of the protein was able to bind to phospholipid micelles and that these species contained 6.5 mol of gla per mole of protein. Esnouf and Prowse have also found that the warfarin-induced zymogen must possess at least 7 gla residues per mole of protein to exhibit coagulant activity (34) . Based upon the above data, it is possible that partially gamma carboxylated forms of prothrombin in the plasma of individuals receiving warfarin might be activated in vivo to thrombin with release of abnormal F1+2 molecules with decreased numbers of gla residues. Under these conditions, the validity of the F,+2 assay as an index for the activation of prothrombin in patients on oral anticoagulants would be dependent on the elimination of two potential sources of error. First, the immunoreactivity of the partially gamma carboxylated F1+2 fragment in this population must be similar to that in normal subjects. Second, the metabolic behavior of partially gamma carboxylated F1,+2 generated in individuals on warfarin must not be altered as compared with the native activation polypeptide.
These two issues were addressed by preparing two batches of F1+2 with < 70% of the full complement of gla residues by thermal decarboxylation (see Methods). This procedure has previously been employed to produce gamma decarboxylated forms of prothrombin and F1 without inducing significant alterations in secondary structure as judged by spectroscopic examination (23) . Our studies revealed that native F1+2 had 9.3 mol of gla per mole of fragment that is concordant with the value of 10 previously obtained by mass spectrometry (35, 36) . The two partially decarboxylated preparations exhibited 5.9 and 6.3 gla residues per mole of protein, respectively (Table I) .
The first potential source of error was examined by determining the relative immunoreactivity of the fully and partially gamma carboxylated forms of F1+2. This property was defined by contrasting the molar concentrations ofthe two F1+2 species required to displace 50% of the immunoprecipitable 1251-F1+2 counts from our specific antibody. The mean slopes and midpoints of the logit-log dose-response curves for the two preparations of partially carboxylated F1+2 were similar to those obtained for the native activation fragment (Table I) . Thus, these data indicate that partially carboxylated and normal forms of F1+2 have virtually identical immunochemical characteristics. It should also be noted that the immunogen utilized to raise the F1+2 antisera was F2, which does not contain any gla residues, and that the immunoreactive site defined by our antibody population is most probably located within the COOH-terminal region of the F2 domain of the F1+2 fragment (12) .
The second potential source of error was investigated by ascertaining the metabolic behavior of fully and partially carboxylated preparations of F1+2 in dogs. We have previously shown that the clearance rate of native '31I-F,+2 in dogs is similar to that in man (17) . To this end, the fully and partially gamma carboxylated forms of F1+2 were radiolabeled with 13'I, and turnover studies with the various radiolabeled species were undertaken. No substantial differences were noted in the metabolism of fully and partially gamma carboxylated forms of F1+2 (Table I) . This impression was confirmed by fitting the data obtained during the 1st 6 h to a two-exponential curve (37) that allowed us to compute several metabolic parameters (38) . ' 3'I-F1+2 plasma radioactivity is described by a two-exponential curve, Cier"' + C2e-r'I (37). The fractional breakdown rate, KB (h-'), was calculated from C1/r1 + C2/r2)-' (38) .
Studies ofpatients with thrombotic diatheses and elevated plasma F,+2 levels before the initiation of anticoagulant therapy Based upon the above data, we conclude that the decrease in F1+2 levels observed in patients on a stable program of oral anticoagulation accurately reflects the diminished activation of prothrombin by Factor Xa. We next proceeded to study the alterations in hemostatic system activation as measured by the RIAs for F1+2, FPA, and PCP during the initiation of warfarin therapy in individuals with a history of recurrent venous thrombosis. We have also examined the changes in the above parameters relative to the intensity of oral anticoagulation in this population as well as the effects ofthis medication on F1+2 levels in subjects with hereditary deficiencies of antithrombin and protein C. The individuals participating in these investigations were selected from a cohort of patients referred to our laboratory for hemostatic evaluation. Patients enrolled in these research protocols had been free of thrombotic complications for at least 3 mo before study. In subjects studied before the institution of antithrombotic therapy, routine coagulation studies, including PT and partial thromboplastin time, were within normal limits. None of the subjects exhibited clinical or laboratory evidence of hepatic or renal dysfunction.
Hemostatic system activation during the initiation oforal anticoagulants. We have carried out detailed investigations of the sequential changes in the levels of F1+2, FPA, and PCP in two patients with a prior history of recurrent venous thromboembolism during the initiation of oral anticoagulation (Fig. 2) .
Subject 1 was a 59-yr-old male who was not congenitally deficient in antithrombin, protein C, or protein S (Fig. 2 A) . The baseline plasma measurements of F1+2, FPA, and PCP in this individual were all substantially elevated at 3.47 nM, 2.1 1 nM, and 3.12 pM, respectively. Treatment was initiated with 7.5 mg of sodium warfarin daily, and the medication dose was adjusted to attain a PT ratio of 1.8 to 2.0. This intensity of anticoagulation was achieved in 5 d. The F1+2 concentration was observed to rise to 4.68 nM after 1 d of therapy and steadily fell in the ensuing days reaching a level of 1.70 nM on day 5 that was within the normal range. Maximal suppression of Factor Xa enzymatic activity was observed on day 17 (Fig. 2 B) . The baseline plasma measurements of F1+2, FPA, and PCP in this woman were 2.67 nM, 0.92 nM, and 2.03 pM, respectively. Treatment was initiated with 10 mg of sodium warfarin for 4 d followed by a maintenance dose of 7.5 mg daily. A PT ratio of 1.7 was achieved by day 6. The plasma F1+2 concentration in this patient also increased to 3.19 nM within the first day of therapy and gradually fell to a level of 1.13 by day 6. A value of 0.56 nM was attained by day 10. The PCP determinations decreased in a manner similar to those observed in patient 1, whereas the plasma FPA levels remained relatively stable throughout the duration of the study. The immunologic level of protein C zymogen declined from 106% of normal to 85% on day 1 and reached a stable concentration of 45% by day 4; the functional level of protein C dropped from a baseline level of 110% of normal to 60% on day 1. Plasma prothrombin measurements as determined by RIA were unchanged at 24 h and decreased to a level of 60% of normal over a 2-wk period, whereas the functional antithrombin determinations did not change appreciably.
The effect of low dose warfarin on the hemostatic mechanism. We next conducted sequential studies of five patients on warfarin regimens of varying intensity (Table II) . The extent of hemostatic system activation as measured by the F1+2, FPA, and PCP assays was evaluated at weekly intervals starting 3 wk after the onset of treatment. The dose of warfarin was adjusted at monthly intervals to achieve a stable intensity of oral anticoagulation. The targeted PT ratios were 1.4 to 1.8 (level I) and 1.0 to 1.3 (level II). To demonstrate that the levels of these in vivo markers of coagulation system activity represented stable parameters characteristic of a particular individual at a given point of time, we obtained blood samples on each subject on multiple occasions at each level of anticoagulant intensity at intervals ranging from weeks to months. In four of the five patients, we were able to discontinue anticoagulation at the completion of our investigations and the levels of F1+2, FPA, and PCP returned to their pretreatment values (data not shown).
Subjects 1 and 2 were the same individuals who had participated in our investigations of alterations in coagulation system activity during the initiation of oral anticoagulation and were studied at two intensity levels. A daily warfarin dose of 5 mg/d resulted in the maintenance of a PT ratio of 1.41 to 1.68 (level I) in subject 1. This level oftherapy caused a suppression of F1+2 levels from a baseline value of 3.47 to 0.37 nM. The FPA and PCP values also decreased from 2.11 nM and 3.12 pM to 1.06 nM and 1.17 pM, respectively. The daily dose of medication was then reduced to 3 mg/d, which resulted in a PT ratio that ranged between 0.90 and 1.06 (level II). The measurements of F1+2, EPA, and PCP were 1.48 nM, 1.25 nM, and 1.20 pM, respectively. Only the F1+2 measurements were significantly different at the two intensity levels of oral anticoagulation. In subject 2, a daily warfarin dose of 7 mg/d resulted in the maintenance of a PT ratio of 1.54 to 1.73 (level I). This resulted in the suppression of F1+2 levels from a baseline value of 2.67 to 0.88 nM. The PCP values also decreased substantially from 2.03 to 0.52 pM, whereas FPA measurements did not change significantly. The daily dose of drug was then reduced to 4 mg/d, which resulted in a PT ratio that ranged between 1.00 and 1.20 (level II). The mean F1+2 level was 1.45 nM, which was within the normal range. The concentrations (17) or protein C.2 In pursuing these investigations, blood samples were also obtained for measurements of F1+2 from relatives with these disorders who had a severe thrombotic diathesis and were chronically maintained on oral anticoagulants.
A total of 12 antithrombin-deficient subjects derived from seven families were studied (Fig. 3 A) . The mean plasma antithrombin concentration as determined by heparin cofactor assay was 47.2%±13.1 of normal, and the median age of this cohort on the date of evaluation was 40 yr. These individuals had a mean PT ratio of 1.85±0.41 (range from 1.31 to 2.44).
The mean plasma F1+2 level was significantly increased in this population as compared with the group of 23 nonantithrombin-deficient patients shown in Fig. 1 who had an equivalent intensity level of oral anticoagulation, 0.714±0.26 nM vs. 0.231±0.24 nM, P < 0.01. This relative resistance to the suppression of Factor Xa enzymatic activity by warfarin as measured by the PT was also evident in subject 2 (Table II) . However, we noted that the antithrombin-deficient subjects constituted an extremely heterogeneous population in terms of the relationship between the level ofF1+2 and the PT ratio. As only three of these 12 individuals have been investigated in the absence of oral anticoagulant therapy, we are unable to draw any conclusions regarding the role that warfarin-induced increments in the plasma antithrombin concentration might play in reducing the extent of prothrombin activation in these subjects.
We have also shown that the infusion of antithrombin concentrate into three stably anticoagulated patients with a deficiency of this protease inhibitor leads to further suppression of plasma F1+2 levels (Table III) . After obtaining baseline blood studies, each subject received an infusion ofthe purified protein via a peripheral vein at a dosage of 25-50 U/kg. Blood samples were obtained by separate venipuncture at various time points after the medication was administered. Our results indicate that the mean plasma antithrombin concentration increased from a mean basal value of48% of normal to a mean level of 120% 6 h after the completion of the infusion. The mean plasma F1+2 measurement decreased from 0.697±0.29 nM to 0.103±0.06 nM. The above results allow us to conclude that the effect of warfarin on hemostatic system activation is modulated by the endogenous heparan sulfate-antithrombin mechanism. The observed effect of warfarin in antithrombin-deficient patients is in sharp contrast to the action of the anticoagulant in 22 individuals from 12 kindreds with heterozygous protein C deficiency (Fig. 3 B) . We 
Discussion
The 4-hydroxycoumarin drugs are widely used oral anticoagulants that function by lowering the plasma activity of the vitamin K-dependent blood coagulation proteins (i.e., prothrombin, Factors VII, Factor IX, Factor X, protein C, and protein S). Numerous clinical trials have shown that these drugs are effective in the treatment of venous thromboembolism (39) (40) (41) . Also, this anticoagulant is of value in the prophylaxis of venous thrombosis in high risk patients (42, 43) and systemic embolism in patients with various types of cardiac disease (44) . Warfarin therapy is usually monitored by the onestage PT, which provides an estimate ofthe functional activity of Factor VII, Factor X, and prothrombin. This assay utilizes various concentrations of animal or human tissue thromboplastin to activate the extrinsic coagulation cascade and thereby convert prothrombin to thrombin under arbitrary in vitro conditions. Despite improvements in the monitoring of therapy with this test in recent years, the optimum level of anticoagulant intensity, i.e., that level which provides protection against thrombosis with a minimal risk of bleeding, has not yet been established.
In this communication, we have employed a series of immunoassays that quantitate the in vivo activities of various steps of the hemostatic mechanism to study patients receiving sodium warfarin. (45) . Given the above data, it was estimated that the t1/2 of fully carboxylated protein C within the circulation is -16 h. The Factor VII coagulant activity determinations followed a pattern virtually identical to the protein C anticoagulant activity measurements that is concordant with the similar t1/2 of these two fully carboxylated coagulation proteins. Factor X levels declined at a slower rate consistent with a t1/2 of -48 h, which is similar to that which has been observed for protein S, another vitamin K-dependent factor (46) . Based upon the above information, it is difficult to determine the net effect of drug-induced alterations of protein C and Factor VII on the in vivo generation of thrombin during the initiation of anticoagulant therapy.
Our studies show an increased extent of prothrombin-tothrombin conversion during the early phase of warfarin therapy. Thus, it would appear that the early in vivo action of the drug on protein C is more profound than its effect on Factor VII. We have also noted that the concentrations of protein C antigen and protein C anticoagulant activity decline at 24 h to an extent similar to that observed by D'Angelo et al. (45) , whereas the levels of PCP do not change appreciably during this time interval. This latter measurement provides an index of the in vivo activation of protein C by thrombin bound to thrombomodulin on the vascular endothelium. Therefore, the elevations in plasma F1+2 levels that occur during the first day of warfarin therapy are best correlated with the decrease in protein C anticoagulant activity rather than a reduced extent of zymogen activation. This phenomenon presumably arises from the diminished ability of partially carboxylated forms of activated protein C to interact with membrane sites on which Factor Va is bound.
Despite having studied a small number of subjects initiating warfarin therapy, we surmise that an early rise in the Factor Xa dependent cleavage ofprothrombin may occur in many individuals with elevated plasma F1+2 values who start this medication and that this effect might be augmented when loading-dose schedules are utilized. The reduced extent of protein C activation that has been observed by us in many nonanticoagulated patients with heterozygous protein C deficiency2 potentially renders these subjects particularly susceptible to an augmented early rise in plasma F1+2 that could lead to warfarin-induced skin necrosis. However clinical studies suggest that only -30% ofthese cases are associated with hereditary protein C deficiency (47) . Indeed, any lesion in the protein C anticoagulant pathway might also predispose affected individuals to the above phenomenon. In this regard, it is of interest to note that this syndrome has recently been described in a patient with heterozygous protein S deficiency (48) .
After the initial rise on day 1, the F1+2 and PCP concentrations gradually fell and reached the normal range by -day 5 of warfarin therapy. At this point in time, it has been observed that the activity levels of Factors IX and X and prothrombin are substantially reduced (49) . Maximal suppression of prothrombin activation was observed 2 wk after the initiation of oral anticoagulation.
The effect of low dose warfarin on the hemostatic mechanism. The substantial suppressive effect of standard warfarin schedules on prothrombin activation in patients without an inherited thrombotic diathesis suggested that a less intense anticoagulation regimen might lead to a significant reduction of elevated plasma F1+2 levels into the normal range rather than to subnormal concentrations. We therefore studied the response of the hemostatic mechanism to a very low intensity anticoagulation program (PT ratio < 1.3) in five patients with a prior history of thrombotic disease. All of these individuals had elevated plasma F1+2 levels before the institution of warfarin therapy. The administration of low doses of the drug led to a decrease in the concentration of this marker into the normal range at a mean PT ratio that was essentialy indistinguishable from untreated subjects.
We have previously shown that patients on oral anticoagulants with PT ratios > 1.5 exhibit a reduction of plasma PCP levels (14) . This effect presumably arises due to diminished thrombin generation with resultant suppression of protein C activation. Furthermore, a decrease in the plasma concentration of protein C and/or its gla content may also contribute to this phenomenon. PCP values were consistently suppressed from their baseline values on the very low intensity warfarin regimen to an extent similar to that observed at more intense levels of anticoagulation. The mean level of FPA did not show a significant decrease in the five patients treated with the very low intensity program. Therefore, our data suggests that F1+2 is a more sensitive marker than either PCP or FPA in differentiating varying intensities of oral anticoagulant therapy.
In the United States, the generally accepted therapeutic range for the PT ratio in patients receiving warfarin has been considered to be 1 (39) (40) (41) . These investigators have demonstrated that a less intense warfarin regimen equivalent to a PT ratio of 1.2-1.3 is as effective as standard anticoagulant therapy in preventing recurrent venous thromboembolism and is associated with a reduced risk of hemorrhagic complications (41) . Other groups have shown that low intensity warfarin schedules resulting in PT ratios between 1.3 and 1.5 are effective for the prophylaxis of venous thrombosis in high risk surgical patients (42, 43) . Our documentation ofthe suppression ofelevated plasma F1+2 levels in individuals with hypercoagulable syndromes into the normal range with a low intensity of anticoagulant therapy is consistent with the above clinical observations.
It must be emphasized that our biochemical observations cannot presently be interpreted as demonstrating a therapeutic effect of very low intensity warfarin schedules. The extent of prothrombin activation at which antithrombotic protection is afforded will need to be determined by properly designed prospective studies with objective clinical endpoints for thrombotic events.
The effect of warfarin on the hemostatic mechanism ofpatients with hereditary deficiencies ofantithrombin and protein C. The presence of F1+2, PCP, and FPA within the blood under normal conditions indicates that hemostatic enzymes are continuously generated within the vascular system. We have previously demonstrated that many nonanticoagulated patients with hereditary deficiencies of antithrombin and protein C have elevated levels of Factor Xa activity as measured by the F1+2 assay (17) .2 The hemostatic system hyperactivity in the antithrombin-deficient individuals could be specifically corrected by raising the plasma levels of the protease inhibitor into the normal range (17) . These studies therefore support the view that the heparin-antithrombin and protein C-thrombomodulin systems are tonically active regulatory mechanisms that limit prothrombin activation in humans.
Warfarin exhibits a major anticoagulant effect on the vitamin K-dependent procoagulant factors as well as a potential "procoagulant action" on the protein C anticoagulant mechanism as outlined above. Hence, it was of interest to evaluate drug-induced alterations of hemostatic system activation in patients with congenital deficiencies of antithrombin or protein C. In the antithrombin-deficient subjects, we were able to show that the imbalance between procoagulant and anticoagulant forces could be corrected with warfarin therapy. However we observed that many of these patients exhibited plasma F1,+2 levels at a given PT ratio that were substantially elevated as compared with anticoagulated individuals without an inherited thrombotic disorder. Normalization of the concentrations of antithrombin in three patients with congenital deficiencies of the protease inhibitor resulted in a further substantial decrease in the plasma levels of F1+2. We speculate that the apparent resistance to warfarin is secondary to an augmented "procoagulant effect" of the drug on the protein C anticoagulant mechanism that is usually masked by the normal functioning of the endogenous heparan sulfate-antithrombin anticoagulant pathway. The markedly suppressed plasma concentrations of F1+2 observed in a few ofthe antithrombin-deficient subjects could potentially be related to increases in the plasma level of the protease inhibitor that have been observed in occasional individuals with this disorder receiving oral anticoagulants (50).
An enhanced "procoagulant effect" of warfarin on the protein C anticoagulant pathway as was observed in patients with antithrombin deficiency might also be expected in individuals with congenital protein C deficiency. However, we noted that the relationship between the suppression of prothrombin activation as measured by the F1+2 assay and the PT ratio in anticoagulated subjects with protein C deficiency was identical to that which was observed in individuals without an inherited thrombotic disorder. These data imply that the chronic administration of warfarin leads to a dominant anticoagulant effect on the vitamin K-dependent procoagulant factors of the hemostatic system as compared with the "procoagulant action" of the drug on the protein C anticoagulant mechanism when the endogenous heparan sulfate-antithrombin anticoagulant pathway is functioning normally.
It is apparent from the above investigations that sensitive immunochemical tools such as the F1+2 assay are able to assess the overall balance between procoagulant and anticoagulant mechanisms in the circulation of patients with thrombotic diatheses receiving oral anticoagulants. Recent clinical studies have demonstrated that low intensity regimens of warfarin provide prophylaxis against venous thrombosis, but the minimal level of oral anticoagulants required in a given patient remains to be determined. The techniques utilized in this communication may be useful in monitoring the in vivo action of low intensity warfarin therapy in clinical trials designed to establish the lowest amount of this medication needed to protect against a thrombotic event. This more sophisticated assay approach may be particularly helpful because of the potential heterogeneity in patient responses to low intensity warfarin regimens depending on the intrinsic activity ofthe endogenous heparan sulfate-antithrombin anticoagulant pathway.
